Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.
Adelia Therapeutics, Inc. is a biopharmaceutical company based in Fitchburg, Massachusetts, focused on developing a drug discovery platform centered on proprietary psychedelics-based therapeutics. Established in 2020, the company specializes in creating tryptamine-based treatments aimed at addressing central nervous system (CNS) disorders, with an initial focus on treatment-resistant depression (TRD). Adelia Therapeutics aims to enhance dosing efficacy and therapeutic indices through its innovative therapeutic approaches.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.